AI and Neurological Rare & Neuroimmune Diseases ── 2026-11-16
New papers on neurological rare and neuroimmune diseases and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 9 disease groups, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by disease: Basic research(0) · ALS(0) · Parkinson's(2) · Hereditary neurodegeneration(0) · Neuromuscular(0) · Multiple sclerosis(0) · NMOSD/MOGAD(0) · Myasthenia gravis(0) · Autoimmune encephalitis/CIDP/GBS(0)
Neurodegeneration and neuroimmunology research and AI
No new qualifying paper for this issue.
ALS: treatment, trials and AI
No new qualifying paper for this issue.
Parkinson's disease and parkinsonism: treatment, trials and AI
- Abstract
OBJECTIVES: Parkinson's disease (PD) is characterized by degeneration of dopaminergic neurons in the substantia nigra, accompanied by increased iron accumulation, particularly in the nigrosome-1 subregion. Differentiating neurodegenerative disorders like PD from non-neurodegenerative causes of parkinsonism can be challenging. In clinically uncertain parkinsonian syndrome (CUPS), dopamine transporter (DAT)-single-photon emission computed tomography (SPECT) can aid diagnosis. However, susceptibility map-weighted imaging (SMWI) provides a promising magnetic resonance imaging (MRI) alternative. We evaluated the diagnostic accuracy and reliability of visual SMWI assessment by radiologists in CUPS and the added value of artificial intelligence (AI)-driven diagnostic software. MATERIALS AND METHODS: Patients with CUPS who underwent DAT-SPECT between January 2019 and July 2023 were included. Four radiologists, blinded to clinical symptoms and diagnosis, visually rated nigrosome-1 on axial SMWI reconstructions as normal, unclear, or abnormal. After the initial assessment, the radiologists re-evaluated the scans with AI-driven software assistance, designed to classify and quantify nigrosome-1 integrity. The reference standard was the final clinical diagnosis incorporating DAT-SPECT results. RESULTS: One hundred eighty patients were included (mean age 67.9, range 31-86, 120 males), 84 with neurodegenerative and 96 with non-neurodegenerative parkinsonism. Mean diagnostic accuracy was 80% (range 73-83%), with substantial inter-rater reliability (Fleiss κ 0.65). With software assistance, diagnostic accuracy improved to 87% (range 85-91%), and inter-rater agreement increased to almost perfect (Fleiss κ 0.86). CONCLUSION: SMWI, particularly with AI-driven software assistance, is a promising and accessible MRI-based technique that may support the diagnostic workup in clinically uncertain parkinsonism, aiding the distinction between neurodegenerative and non-neurodegenerative causes. KEY POINTS: Question Can susceptibility map-weighted imaging (SMWI) reliably differentiate neurodegenerative from non-neurodegenerative parkinsonism in clinically uncertain cases, and does artificial intelligence (AI)-driven software assistance improve radiologist performance?
Findings: Visual assessment had an accuracy of 80%, with substantial inter-rater reliability. AI-driven software assistance increased accuracy to 87% and improved inter-rater reliability. Relevance statement SMWI can differentiate neurodegenerative from non-neurodegenerative parkinsonism in clinically uncertain cases and may support the diagnostic process by offering an accessible MRI-based technique, facilitating an efficient diagnostic workup, and enabling early diagnosis in clinically uncertain parkinsonism.
Journal IF-equivalent: 6.4 (OpenAlex 2-year mean citedness, value as of 2026-11-15, retrieved 2026-11-16; not the official Clarivate IF)Reference: Wallert ED, Beudel M, Keil VC, Sánchez Aliaga E, Barkhof F, van Mierlo T, et al. Diagnostic accuracy and reliability of susceptibility map-weighted imaging in patients with clinically uncertain parkinsonian syndromes. Eur Radiol Exp. 2026 Nov 14;10(1):184. doi:10.1186/s41747-026-00832-w. PMID: 43034231.Checked: Abstract only - Abstract
Parkinson's disease is characterized by progressive motor impairments that require continuous and objective monitoring beyond episodic clinical assessments. This study presents the design and technical validation of an Internet of Things-based wearable system for inertial gait monitoring, integrating a smartwatch sensing node, a mobile gateway, cloud analytics, and a web-based dashboard. We conducted a standardized experimental protocol with 40 apparently healthy adults performing three walking conditions (slow, normal, and fast), yielding 120 gait segments acquired in fixed 10-second windows. We conducted this study under controlled conditions to establish a baseline for future clinical validation in Parkinson’s disease populations. We extracted temporal, spectral, and step-related features from triaxial accelerometer signals and used them to train a supervised gait classification model based on a Random Forest algorithm, evaluated using stratified five-fold cross-validation. The proposed classifier achieved consistent discrimination performance under inter-subject variability. Although this work is limited to healthy participants, the results demonstrate the technical feasibility and reliability of the proposed system. The platform provides a technically validated foundation for future deployment in Parkinson's disease populations, supporting the development of monitoring applications and digital motor biomarkers.
Journal IF-equivalent: 1.6 (OpenAlex 2-year mean citedness, value as of 2026-11-15, retrieved 2026-11-16; not the official Clarivate IF)Reference: Alcaraz-Vázquez M, Alarcón-Paredes A, Saldaña-Pérez AMM, Guzmán-Guzmán IP, Alonso-Silverio GA. Machine Learning–Powered Wearable Sensors for Gait Analysis: A Technical Validation in Healthy Subjects Toward Parkinson’s Disease Monitoring. Rev Mex Ing Biomed. 2026 Nov 14;47(3):e2026-1658. doi:10.17488/rmib.47.3.1658.Checked: Abstract only
See all 2 Parkinson's papers →
Hereditary neurodegenerative diseases: treatment, trials and AI
No new qualifying paper for this issue.
Neuromuscular diseases (muscular dystrophy, SMA): treatment, trials and AI
No new qualifying paper for this issue.
Multiple sclerosis: treatment, trials and AI
No new qualifying paper for this issue.
NMOSD and MOGAD: treatment, trials and AI
No new qualifying paper for this issue.
Myasthenia gravis: treatment, trials and AI
No new qualifying paper for this issue.
Autoimmune encephalitis, CIDP and Guillain-Barre syndrome: treatment, trials and AI
No new qualifying paper for this issue.